Background: Non-small-cell lung cancer (NSCLC) is a deadly cancer with high mortality rate. Drug resistance represents a main obstacle in NSCLC treatment. High mobility group box-1 (HMGB1) protein promotes drug resistance in NSCLC cells by activating protective autophagy. Methods: In the current study, we investigated the regulatory role of microRNA-142-3p (miR-142-3p) in HMGB1-mediated autophagy of NSCLC cells and its impact on drug resistance of NSCLC in vitro and in vivo. HMGB1 was identified as a putative target gene of miR-142-3p by in silico analysis. Our luciferase reporter assay results confirmed that miR-142-3p directly targets the 3'-UTR of HMGB1 in NSCLC cells. Results: MiR-142-3p overexpression suppressed while miR-142-3p knockdown increased HMGB1 mRNA and protein expression. Starvation induced HMGB1 expression and activated autophagy in NSCLC cells. The starvation-induced autophagy was inhibited by miR-142-3p overexpression or HMGB1 knockdown. Moreover, miR-142-3p overexpression or HMGB1 knockdown increased PI3K, Akt, and mTOR phosphorylation. Inhibition of PI3K or mTOR restored starvation-induced autophagy inhibited by miR-142-3p overexpression or HMGB1 knockdown. Conclusions: These results demonstrated that miR-142-3p regulates starvation-induced autophagy of NSCLC cells by directly downregulating HMGB1 and subsequently activating the PI3K/Akt/mTOR pathway. Further, miR-142-3p overexpression inhibited anticancer drug-induced autophagy and increased chemo-sensitivity of NSCLC in vitro and in vivo. These findings shed light on the therapeutic potential of miR-142-3p in combating acquired NSCLC chemo-resistance.
Introduction
Non-small-cell lung cancer (NSCLC) is one of the most deadly cancers worldwide [1] . Drug resistance, intrinsic or acquired, limits the efficacy of conventional chemotherapy and biological therapies, and thus represents a major obstacle in NSCLC treatment [2] .
NC for anti-miR-142-3p) were synthesized at GenePharma (Shanghai, China). SiRNA against HMGB1 was purchased from Genechem (Shanghai, China). The PI3K inhibitor LY294002 was purchased from Cell Signaling Technology Inc. (USA). Adriamycin (ADM), cisplatin (DDP), and the mTOR inhibitor rapamycin were all from Sigma-Aldrich (USA).
Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
Total RNA was extracted from A549 cells using an RNeasy Mini Kit (Qiagen, USA) following manufacturer's instructions. The RT primers for miRNA cDNA synthesis are: MiR-142-3p, GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCCATAAA; U6, CGAGCACAGAATCGCTTCACGAATTTGCGTGTCAT. The primers for mRNA detection are: miR-142-3p, 5'-GTCGTATCCAGTGCAGGG-3'(forward) and 5'-CGACGTGTAGTGTTTCCTA-3' (reverse); HMGB1, 5'-GATGGGCAAAGGAGATCCTA-3' (forward) and 5'-CTTGGTCTCCCTTTGGGG-3' (reverse). Real-time quantitative PCR (qRT-PCR) was performed using a SYBR green qPCR SuperMix-UDG kit (Life Technologies, USA) on an ABI PRISM 7300 system (Applied Biosystems). Ct values of HMGB1 mRNA were normalized to β-actin. Relative expression was calculated using the ΔΔ Ct method.
Western blot analysis
Cell lysates and tumor tissue homogenates (50 µg per sample) were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, USA). After blocking in 5% nonfat milk for 1 h, the membranes were incubated with anti-HMGB1, anti-p62, anti-LC3, anti-PI3K, anti-p-PI3K, anti-mTOR, anti-p-mTOR, anti-Akt, anti-p-Akt, or anti-β-actin at 4°C overnight. After washing with PBS, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody for 2 h at room temperature. Signals were detected using an ECL detection system (Bio-Rad, USA). All primary antibodies except anti-β-actin were from Cell Signaling Technology Inc. Anti-β-actin was purchased from Sigma-Aldrich.
Luciferase reporter assay
The putative miR-142-3p binding site in the 3'-UTR of HMGB1 was predicted using miRanda-mirsVR (http://www.microrna.org/microrna/home.do). A fragment containing the putative miR-142-3p binding site was amplified and subcloned into the pGL3 plasmid to generate the pGL3-HMGB1 3'-UTR-wild type. A fragment containing the mutant binding site with six-base changes was created using the Quick-Change Site Directed Mutagenesis Kit (Invitrogen) and subcloned into the pGL3 plasmid to generate the pGL3-HMGB1 3'-UTR-mutant. A549 cells were seeded in 96-well plates (1,000 cells/well) and cultured overnight. On the next day, the cells were co-transfected with 1.5 ng of pGL3-HMGB1 3'-UTR-wild type/pGL3-HMGB1 3'-UTRmutant and with 100 nM of either miR-142-3p or miR-NC using Lipofectamine 2000 (Invitrogen). Luciferase activity was detected 72 h after transfection using the Dual-Luciferase Reporter Assay Kit (Promega, USA) on a TD20/20 Luminometer (Turner Designs).
Detection of autophagosomes with GFP-LC3 labeling
A549 cells were transfected with GFP-LC3 cDNA using Lipofectamine 2000 reagent (Invitrogen) according to the supplier's protocol. The transfected cells were seeded in six-well plates (5×10 5 cells/well) and cultured overnight. On the next day, cells were transfected with 100 nM miR-142-3p or miR-NC for 72 h using Lipofectamine 2000 (Invitrogen). Cells were subsequently subjected to 20 min starvation in serum-free Hank's balanced salt solution (HBSS). GFP-LC3-labeled vacuoles (autophagosomes) were counted under a fluorescence microscope (Olympus IX70). To assess drug-induced autophagy, A549 cells labeled with GFP-LC3 were transfected with 100 nM miR-142-3p or miR-NC for 24 h. The cells were subsequently incubated with ADM (5 M), DDP (20 µM) or vehicle alone (control) for 48 h and subjected to autophagosome detection by fluorescence imaging.
Cell proliferation assay A549 cells transfected with 100 nM miR-142-3p or miR-NC for 24 h were seeded in 96-well plates (5×10
Apoptosis assays
Cell apoptosis was assessed by measuring the activation of caspase-3 and TUNEL staining. The caspase-3 activity was determined using a caspase-3 assay kit from BioVision Inc. (Mountain View, CA, USA) following manufacturer's instructions. TUNEL assays were performed using the in situ Cell Death Detection Kit (Roche Diagnostics GmbH, Mannheim, Germany) following manufacturer's instructions. The total number of cells in a given area was determined by DAPI staining. The apoptotic index is presented as the percentage of TUNEL-positive cells.
Preparation of stable cell lines A549 cells stably expressing miR-142-3p or miR-NC were used to generate NSCLC xenograft model. In brief, A549 cells were infected with lentiviruses carrying miR-142-3p or miR-NC (Genomeditech Inc., Shanghai, China) for 48 h. The cells were subsequently selected by puromycin for 1 weeks for stable expression of miR-142-3p or miR-NC.
Animal experiments
Male nude mice (5 weeks old) were purchased from the Shanghai Laboratory Animal Company (SLAC, Shanghai, China). A549 cells stably expressing miR-142-3p or miR-NC (5×10 6 cells in 100 μl phosphatebuffered saline (PBS)) were subcutaneously injected into the right flank of mice (n=8 per group). After one week, DDP (2.0 mg/kg) or ADM (2.0 mg/kg) was administered via intraperitoneal injection three times a week for three weeks. The tumor volume was measured once every four days using the modified ellipse volume formula: volume = (height*width*depth)/2. At the end of treatment, the mice were sacrificed and the tumors were collected. The tumor tissues were subjected to immunohistological analysis by hematoxylin and eosin (H&E), proliferating cell nuclear antigen (PCNA), and TUNEL staining. Tumoral HMGB1, LC3 and p62 levels were determined by western blot analysis.
Statistical analysis
All data are presented as means ± standard deviation (SD). Two-way ANOVA was applied to interpret the differences between treatment groups. Differences with a P value < 0.05 were considered statistically significant.
Results

HMGB1 is a direct target of miR-142-3p in human NSCLC cells
We first examined the expression of miR-142-3p in normal human bronchial epithelium (HBE) cells and A549 human NSCLC cells by qRT-PCR. As shown in Figure 1A , the expression of miR-142-3p in A549 cells was significantly lower than that in HBE cells. This was consistent with previous findings of miR-142-3p downregulation in NSCLC [18] . MiR-142-3p has been reported to directly regulate HMGB1 in human lung cancer cells [18] . In this study, we independently identified a putative miR-142-3p binding site in the 3'-UTR of HMGB1 (Fig.  1B ) using miRanda-mirsVR (http://www.microrna.org/microrna/home.do). To find out whether HMGB1 is a bona fide target of miR-142-3p in NSCLC cells, we prepared luciferase reporter expression systems comprising the 3'-UTR of human HMGB1 containing the putative miR-142-3p binding site (wild type or mutant) (Fig. 1B) . Transient co-transfection of the reporter construct containing the wild type 3'-UTR with miR-142-3p into A549 cells resulted in approximately 60% loss of luciferase reporter activity (P<0.01, Fig. 1C ). However, miR-142-3p co-transfection did not repress the luciferase activity when the wild type 3'-UTR was replaced with the mutant 3'-UTR in the luciferase reporter system (Fig. 1C) . We next examined whether miR-142-3p could regulate endogenous HMGB1 expression in NSCLC cells. Our qRT-PCT results showed that miR-142-3p expression was significant elevated by miR-142-3p transfection while reduced by anti-miR-142-3p transfection (Fig. 1D) . We detected decreased HMGB1 mRNA and protein levels in A549 cells transfected with miR-142-3p, meanwhile, increased HMGB1 levels were found in A549 cells transfected with antimiR-142-3p (P<0.01, Fig. 1E, 1F) . Taken together, these results confirmed that miR-142-3p directly downregulates HMGB1 in NSCLC cells by targeting the 3'-UTR of HMGB1.
MiR-142-3p overexpression inhibits starvation-induced autophagy of human NSCLC cells
It has been reported that HMGB1 knockdown by RNA interference inhibits autophagy and promotes chemo-resistance in NSCLC cells [30, 31] . Based on these previous findings, we speculated that miR-142-3p could regulate NSCLC cell autophagy by downregulating HMGB1. To test this, we investigated the effects of miR-142-3p overexpression on starvationinduced autophagy in human NSCLC cells. Autophagy is characterized by the formation of autophagosomes and autolysosomes. Microtubule-associated protein-1 light chain 3 (LC3), a major constituent of the autophagosome, is a reliable marker of autophagosomes. In this study, we used NSCLC cells transfected with green fluorescent protein (GFP)-tagged LC3 (GFP-LC3) to detect autophagosome formation. Nutrient starvation for 20 min in serumfree HBSS medium significantly induced the formation of GFP-LC3-labeled vacuoles in miR-NC-transfected but not miR-142-3p-transfected A549 cells ( Fig. 2A) , indicating that miR-142-3p overexpression suppresses starvation-induced autophagosome formation. To further characterize autophagy, we determined the conversion of LC3-I to LC3-II and the protein level of p62 using western blot analysis. The conversion of soluble LC3-I to lipid bound LC3-II is associated with the formation of autophagosomes during autophagy. P62 is an LC3-binding protein that is degraded through the autophagy-lysosomal pathway [32] . Our results showed that nutrient deprivation for 4 h resulted in increased LC3-II to LC3-I ratio as well as decreased p62 level. These autophagy-associated changes were attenuated by miR-142-3p overexpression (P<0.01, Fig. 2B, 2C) , further supporting that miR-142-3p overexpression inhibits starvation-induced NSCLC cell autophagy. Interestingly, miR-142-3p overexpression also led to decreased LC3-II/LC3-I ratio and increased p62 level in nonstarved cells (P<0.05, Fig. 2B, 2C ), suggesting that miR-142-3p overexpression protects NSCLC cells from autophagy even under normal, nonstressed conditions. 
MiR-142-3p regulates starvation-induced autophagy of human NSCLC cells through HMGB1
To reveal the role of endogenous miR-142-3p in NSCLC cell autophagy, we examined the effects of miR-142-3p knockdown. In contrast to miR-142-3p overexpression, knockdown of endogenous miR-142-3p by anti-miR-142-3p transfection led to significantly increased LC3-I to LC3-II conversion and decreased p62 level in nutrient-deprived A549 cells (Fig.  3A) . These results provided evidence that endogenous miR-142-3p in A549 cells functions to suppress starvation-induced autophagy. Interestingly, miR-142-3p knockdown also increased autophagic activity in nonstarved A549 cells (Fig. 3A) , showing that endogenous miR-142-3p protects A549 cells from autophagy even under normal, nonstressed conditions. Importantly, these anti-and pro-autophagic effects of miR-142-3p overexpression and knockdown were accompanied by down-and up-regulation of HMGB1, respectively (Fig.  3A) , and HMGB1 knockdown by si-HMGB1 transfection downregulated starvation-induced autophagy (Fig. 3B) . These data supported that miR-142-3p inhibits starvation-induced autophagy of NSCLC cells by downregulating HMGB1.
MiR-142-3p overexpression inhibits starvation-induced autophagy of human NSCLC cells through the PI3K/Akt/mTOR pathway
The PI3K/Akt/mTOR pathway has been implicated in drug-induced autophagy in cancer cells [33] [34] [35] . In NSCLC, the anti-tumor drug platycodin-D (PD) has been shown to induce autophagy in A549 cells by inhibiting the PI3K/Akt/mTOR and activating the JNK and p38 MAPK signaling pathways [35] . In this study, we found that inhibition of starvationinduced autophagy by miR-142-3p overexpression or HMGB1 knockdown in A549 cells was accompanied by increased PI3K, Akt, and mTOR phosphorylation (P<0.01, Fig. 4A ). To confirm the involvement of the PI3K/Akt/mTOR pathway in the effects of miR-142-3p, we tested the PI3K inhibitor LY294002 and the mTOR inhibitor rapamycin in A549 cells transfected with miR-142-3p or si-HMGB1. The results showed that blocking the PI3K/Akt/ mTOR signaling pathway with either LY294002 or rapamycin restored starvation-induced autophagy inhibited by miR-142-3p or si-HMGB1 transfection (Fig. 4B, 4C ). LY294002 or rapamycin treatment, however, did not affect HMGB1 expression (Fig. 4B, 4C ). Taken together, these results confirmed that miR-142-3p inhibits starvation-induced NSCLC cell autophagy by modulating the activity of the PI3K/Akt/mTOR pathway through its target HMGB1.
MiR-142-3p overexpression inhibits anticancer drug-induced autophagy of human NSCLC cells through HMGB1
Chemotherapeutic drugs such as cisplatin (DDP) can induce chemo-resistance of NSCLC cells by activating HMGB1-mediated protective autophagy [31] . HMGB1 silencing prevents drug-induced autophagy, and thereby restores chemo-sensitivity of NSCLC [31] . Having shown that miR-142-3p inhibits starvation-induced autophagy by downregulating HMGB1, we speculated that miR-142-3p might also inhibit drug-induced autophagy by the same mechanism. To investigate this hypothesis, we tested the effects of the anticancer drugs ADM and DDP. In alignment with previous findings [31] , ADM and DDP induced HMGB1-mediated autophagy in A549 cells as indicated by increased HMGB1 expression along with increased autophagosome formation, LC3-I to LC3-II conversion, and p62 degradation (P<0.01, Fig  5A, 5B) . In alignment with our speculation, the HMGB1-mediated autophagy of A549 cells induced by ADM and DDP was inhibited by miR-142-3p overexpression (P<0.01, Fig 5A, 5B) . lung cancer [39] . Better understanding of autophagy regulation and its impact on treatment outcome will potentially allow us to identify novel therapeutic strategies to improve cancer treatment.
Many studies have shown that antitumor agents activate protective autophagy in NSCLC cells, causing acquired chemo-resistance [40] [41] [42] . Autophagy inhibition can overcome both ) stably expressing miR-142-3p or miR-NC were subcutaneously injected into the right flank of male nude mice. After one week, DDP (2.0 mg/kg) or ADM (2.0 mg/kg) was administered via intraperitoneal injection three times a week for three weeks. A) Tumor volume measured once every 4 days (n = 6). B) Tumoral HMGB1, LC3-II, LC3-I, and p62 levels determined by western blot analysis (n = 3). C) H&E (original magnification, ×400), PCNA(original magnification, ×200), and TUNEL staining of tumor tissue sections (original magnification, ×200 the innate and acquired drug resistance of NSCLC, and thus represents a novel strategy to broaden the spectrum of NSCLC treatment [42] [43] [44] . In particular, autophagy inhibition has been exploited to improve the efficacy of small-molecule EGFR-tyrosine kinase inhibitors in the treatment of NSCLC patients [39, 44] . Autophagy inhibitors in current NSCLC clinical trials include hydroxychloroquine (HCQ) and chloroquine (CQ) [39] . HCD and CD are US FDA-approved malaria drugs that inhibit autophagy at a late stage by blocking lysosomal acidification. In addition to HCD and CD, identification of novel and effective strategies to inhibit autophagy in NSCLC cells is needed.
A recent study has revealed that miR-143 inhibits NSCLC cell proliferation by targeting the autophagy gene, autophagy-related 2B [45] . HMGB1 is present at increased levels in NSCLC patients [46] . HMGB1-mediated autophagy has been reported to contribute to acquired NSCLC chemo-resistance [30, 31] . In this study, we found that nutrient deprivation as well as the anticancer drug ADM or DDP induced HMGB1-mediated autophagy of NSCLC cells. This HMGB1-mediated autophagy was prevented by miR-142-3p overexpression. Our luciferase reporter assay results showed that miR-142-3p can directly downregulate HMGB1 in NSCLC cells by targeting its 3'-UTR. The PI3K/Akt/mTOR pathway, which is a key regulator of autophagy, has been implicated in HMGB1-mediated autophagy in leukemia cells [28] . In the current study, we found that the PI3K/Akt/mTOR pathway is involved in HMGB1-mediated autophagy induced by starvation, and miR-142-3p overexpression inhibits NSCLC cell autophagy by activating the PI3K/Akt/mTOR pathway through HMGB1. Finally, our results showed that miR-142-3p overexpression also inhibits anticancer drug-induced, HMGB1-mediated autophagy of NSCLC cells to increase the chemo-sensitivity of NSCLC in vitro and in vivo.
HMGB1 is involved in major DNA repair pathways and regulates cell death and survival [27] . Xiao and coworkers have reported that miR-142-3p directly targets HMGB1 to inhibit NSCLC cell proliferation and induce cell apoptosis [18] , but the underlying mechanisms have not been elaborated. Our findings suggest that the in vitro anti-NSCLC properties of miR-142-3p reported by Xiao et al. could be at least partially mediated by downregulation of HMGB1-mediated autophagy. Findings from Xiao's and our work suggest that the downregulated miR-142-3p expression detected in NSCLC tissues and cells could be responsible for the upregulated HMGB1 expression in this malignancy, and the miR-142-3p/HMGB1 signaling likely contributes to both NSCLC tumorigenesis and chemo-resistance. Targeting the miR-142-3p/HMGB1 signaling might be an effective strategy to find novel therapeutic agents for NSCLC.
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